Abstract: Provided herein are compounds, compositions, conjugates and methods for the treatment of diseases, and/or conditions such as, but not limited to, proliferative diseases. In certain embodiments, compounds, compositions, and conjugates are provided, which include cyclodextrin-based linker-payloads and protein conjugates thereof, and/or in combination with other agents. By administering these compounds, compositions, and conjugates as described herein to specific target cells, side-effects due to non-specific binding phenomena, for example, to non-target cells are reduced.

Abstract: A system for remediation of perfluoroalkyl substances (PFASs) has a multiplicity of ?-cyclodextrins (?-CDs) and/or modified ?-CDs combined with a vehicle additive, and a delivery device. Modified ?-CDs can contain a single amine functionality at a single primary carbon or single secondary carbon of the ?-CD. The vehicle additive can be powdered activated carbon (PAC). The delivery device is a column, a pouch, a packet, or a sheet that can permit the contacting of a fluid environment with the ?-CDs and vehicle additive. The system of remediation can be used for a fluid environment or for biological organisms. CD-based fluorescent sensors can detect PFASs in the environment.

Abstract: The present invention relates to a compound which is a di- and/or a tristyrylphenol monoglycidyl ether adduct of the compound of Formula I: where m is from 1 to 60. The compound of the present invention is useful as an open time additive in coatings formulations.

Abstract: A nucleophilic substitution reaction to crosslink cyclodextrin (CD) polymer with rigid aromatic groups, providing a high surface area, mesoporous CD-containing polymers (P-CDPs). The P-CDPs can be used for removing organic contaminants from water. By encapsulating pollutants to form well-defined host-guest complexes with complementary selectivities to activated carbon (AC) sorbents. The P-CDPs can rapidly sequester pharmaceuticals, pesticides, and other organic micropollutants, achieving equilibrium binding capacity in seconds with adsorption rate constants 15-200 times greater than ACs and nonporous CD sorbents. The CD polymer can be regenerated several times, through a room temperature washing procedure, with no loss in performance.

Abstract: An additive composition for use in a diesel fuel formulation, comprising a cetane improver in an inclusion complex with a modified cyclodextrin of formula (I): wherein n is an integer from 6 to 20, and R1, R2 and R3 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted aryl and carbonyl, provided that R1, R2 and R3 are not all hydrogen. Also provided is a diesel fuel formulation comprising the additive composition, and the use of a modified cyclodextrin (I) as a vehicle for a cetane improver in an additive composition or diesel fuel formulation.

Abstract: The present invention relates to derivatized cyclofructan compounds, compositions comprising derivatized cyclofructan compounds, and methods of using compositions comprising derivatized cyclofructan compounds for chromatographic separations of chemical species, including enantiomers. Said compositions may comprise a solid support and/or polymers comprising derivatized cyclofructan compounds.

Abstract: The invention relates to a complex made of ?-cyclodextrin and a halogenated ether, characterized by a content of the halogenated ether of at least 3 wt % of the total weight of the complex.

Abstract: Methods and compositions relating to CDP-epothilone conjugates are described herein.

Abstract: The present invention relates to methods of isolating and purifying sulforaphane. More specifically, the present invention relates to methods of isolating and purifying sulforaphane from natural sources. The present invention also relates to methods of forming high purity complexes of sulforaphane with cyclodextrin.

Abstract: A means for selectively removing ET under coexistence of a substance showing a negative charge, such as nucleic acid is described. Endotoxin is selectively removed by bringing a polymer obtained by crosslinking cyclodextrin with an isocyanate-based crosslinking agent in contact with a solution containing endotoxin and the substance showing the negative charge such as nucleic acid.

Abstract: The invention provides an industrially advantageous method for the production of hydroxyalkylated polyrotaxanes. The method of producing hydroxyalkylated polyrotaxane includes reacting a polyrotaxane with a cyclic ether represented by Formula (1) in the presence of water and an organic base, wherein the polyrotaxane includes hydroxyl group-containing cyclic molecules, a linear molecule threaded through the cyclic molecules to form a clathrate, and blocking groups at both ends of the linear molecule to prevent the separation of the cyclic molecules from the linear molecule.

Abstract: Methods for performing analytical reactions and compositions for use in such methods, where the methods have reduced signal levels deriving from non-specific adsorption of detected reagents to other components of the analytical method, e.g., other reagents, solid phase components, vessels, etc.

Abstract: Methods and compositions relating to CDP-proteasome inhibitor conjugates are described herein.

Abstract: A modified starch, exhibits: a weight-average molecular weight ranging from 250 000 to 2 000 000 Da; a solubility, measured according to a test A, ranging from 50 to 85%. A process for the manufacture of the starch and a process to the use thereof in the manufacture of an aqueous binder are also described.

Abstract: Compounds which inhibit Wza-mcdiated polysaccharide transport are useful in the prevention or treatment of bacterial infection, in particular of E. coli infection. The compounds are typically cyclic oligosaccharides such as cyclodextrins, which bear positively charged functional groups at the primary carbon position.

Abstract: Methods and compositions relating to CDP-epothilone conjugates are described herein.

Abstract: Disclosed is a method for preparing a mixture of malto-oligosaccharides. Generally, a dry-milled corn fraction, such as a corn flour from which germ and fiber have been removed, is subjected to hydrolysis, typically catalyzed with acid or an enzyme such as an ?-amylase enzyme, under conditions suitable to form a mixture of malto-oligosaccharides. A gluten fraction is removed and the enzyme is inactivated, such as with heat. The mixture of malto-oligosaccharides then may be recovered from remaining solids and purified.

Abstract: Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.

Abstract: Provided herein are ready-to-use premixed bolus injection pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.

Abstract: Since a compound represented by formula (I) wherein all of the symbols are the same as defined in the specification, a salt thereof, a solvate thereof, a prodrug thereof, a mixture with a diastereomer thereof in an arbitrary ratio, or a cyclodextrin clathrate thereof have a contracting activity of bladder detrusor and a relaxing activity of urethral sphincter, they can ameliorate bladder contraction dysfunction and/or urethral relaxation dysfunction, and for example, are effective for underactive bladder. Additionally, the compound of the present invention has little risk of side effects on the urinary system, the circulatory system and the digestive system, and exhibits excellent pharmacokinetics, such as oral absorbability etc. Therefore, the compound of the present invention is useful as a superior agent for preventing, treating and/or ameliorating underactive bladder.

Abstract: The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-?-cyclodextrin or sulfobutylether-7-?-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or inhibitor of tumor metastasis.

Abstract: The present invention aims to provide a method of producing a powdered hydrophilic modified polyrotaxane, which enables production of a powdered hydrophilic modified polyrotaxane excellent in storage stability in an industrially advantageous way.

Abstract: The present invention aims to provide a method of producing a hydrophilic modified polyrotaxane, which enables production of a hydrophilic modified polyrotaxane excellent in storage stability in an industrially advantageous way. The present invention provides a method of producing a hydrophilic modified polyrotaxane, comprising: a hydrophilic modification step of preparing a solution of a hydrophilic modified polyrotaxane by modifying all or part of hydroxy groups on a cyclodextrin of a polyrotaxane with hydrophilic modifying groups, the polyrotaxane containing the cyclodextrin, a polyethylene glycol included in the cavities of the cyclodextrin molecules in a skewered manner, and a capping group that is placed at each end of the polyethylene glycol and prevents dissociation of the cyclodextrin molecules from the polyethylene glycol; and a drying step in which the prepared solution of the hydrophilic modified polyrotaxane is formed into a thin film state and dried.

Abstract: Methods for performing analytical reactions and compositions for use in such methods, where the methods have reduced signal levels deriving from non-specific adsorption of detected reagents to other components of the analytical method, e.g., other reagents, solid phase components, vessels, etc.

Abstract: The present invention aims to provide a method for producing a refined polyrotaxane which includes an industrially advantageous method of producing a polyrotaxane that has excellent storage stability. The method for producing a refined polyrotaxane includes the step of heat-cleaning a polyrotaxane with a cleaning medium, the polyrotaxane containing cyclodextrin molecules, a polyethylene glycol which is included in the cavities of the cyclodextrin molecules in a skewered manner, and a capping group that is placed at each end of the polyethylene glycol and prevents dissociation of the cyclodextrin molecules from the polyethylene glycol.

Abstract: 6-deoxy-6-thioether-amino acid cyclodextrin derivative is obtained by condensing an amino acid derivative with halogenated cyclodextrin in presence of alkali. The 6-deoxy-6-thioether-amino acid cyclodextrin derivative includes 6-deoxysulfinyl-6-thioether-amino acid cyclodextrin derivative and 6-deoxysulfonyl-6-thioether-amino acid cyclodextrin derivative. Compounds provided are for reversing neuromuscular relaxation in patients and animals induced by muscular relaxants. The compounds are able to rapidly reverse and antagonize muscular relaxation induced by muscular relaxants and can be administrated in preparing a drug having an antagonist effect on muscular relaxation. The compounds have a general formula (I).

Abstract: A polyrotaxane containing an affinity binding group has been designed and prepared. The polyrotaxane of the invention can be used for characterization and determination of the three-dimensional structures of biological molecules, such as proteins.

Abstract: Chiral salts comprising anionic cyclodextrin derivatives with particular types of non-metal cations are provided. The anionic CD derivative salts can serve as ionic liquids and can possess substantial advantages over currently commercially available ionic liquids particularly for use as chiral phase transfer catalyst, chiral reaction medium, chiral extraction medium, and/or as chiral additive to a chemical process. Methods of preparing the same are provided.

Abstract: A superhydrophilic amphiphilic copolymer and process for making the superhydrophilic amphiphilic copolymer includes a low molecular weight polysaccharide modified with a hydrophobic reagent, such as substituted succinic anhydride. The superhydrophilic amphiphilic copolymer system generates stable foam for use in applications, such as healthcare formulations, with low irritation of the eyes and skin.

Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

Abstract: Methods and compositions relating to CDP-epothilone conjugates are described herein.

Abstract: Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.

Abstract: The present invention relates to substituted cyclodextrin derivatives which are particularly useful intermediates for producing well-defined carboxyalkylated cyclodextrins in contrast with the poorly-defined mixtures available through prior art procedures. The present invention also relates to processes for their preparation in a limited number of steps. These well-defined carboxyalkylated cyclodextrins can be polysulfated according to procedures standard in the art and some of these polysulfates, and alkali salts thereof, have been found to exhibit biologically active properties especially for the treatment and/or prophylaxis of degenerative joint diseases (e.g. osteoarthritis) or heparin-induced thrombocytopenia, or for cartilage repair or connective tissue repair.

Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

Abstract: There is provided a material that after the formation of a cured film, exhibits high solvent resistance, liquid crystal-alignment properties, heat resistance, and high transparency. A composition for forming thermoset film having photo-alignment properties and containing a component (A) that is a compound having a photo-aligning group and a hydroxy group, a component (B) that is a polymer having any one of or both of a hydroxy group and a carboxy group, and a component (C) that is a crosslinker.

Abstract: The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-?-cyclodextrin or sulfobutylether-7-?-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or inhibitor of tumor metastasis.

Abstract: The present invention provides stable medicament-containing chewing gum compositions comprising an inclusion complex comprising cyclodextrin and one or more active compound(s) according to formula I, such as cetirizine, and methods for preparing such chewing gum.

Abstract: The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of lmatinib mesylate as an intermediate for the preparation of pharmaceutical compositions.

Abstract: The present invention relates to pharmaceutical compositions containing substituted 6-deoxy-6-sulfanylcyclodextrins as well as their use as osmotic agents, in particular for use in dialysis therapy.

Abstract: The present invention aims at providing a novel indocyanine compound solving problems of conventionally used indocyanine green, such as solubility in water or physiological saline, a synthesis method and a purification method thereof, and a diagnostic composition including the novel indocyanine compound. Further, provided are a method for evaluating biokinetics of the novel indocyanine compound and a device for measuring biokinetics, and a method and a device for visualizing circulation of fluid such as blood in a living body, which utilize the diagnostic composition. Also, found are a novel indocyanine compound in which a hydrophobic moiety in a near-infrared fluorescent indocyanine molecule is included in a cavity of a cyclic sugar chain cyclodextrin to cover the hydrophobic moiety in the indocyanine molecule with the glucose, and a synthesis method and a purification method thereof.

Abstract: The invention relates to novel fredericamycin derivatives, to drugs containing said derivatives or the salts thereof, and to the use of the fredericamycin derivatives for treating diseases, especially cancer diseases.

Abstract: The invention relates to a complex made of ?-cyclodextrin and a halogenated ether, characterized by a content of the halogenated ether of at least 3 wt % of the total weight of the complex.

Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

Abstract: A new class of non-viral transduction vectors that can be used for both in vivo and in vitro applications, including, a gene transfer vector that has comparable efficiency to a viral vector without the potential for a life-threatening immune response is provided. Complexes including a cellular delivery molecule or agent that can facilitate the translocation of the complex or portion thereof into cells is also provided. The cellular delivery molecules may include one or more polymers, e.g., polyamides, dendritic macromolecules and carbohydrate-containing degradable polyesters.

Abstract: Provided herein are ready-to-use premixed bolus injection pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.

Abstract: A method for producing an active esterified polysaccharide, the method including: subjecting a carboxy group of a carboxy group-containing polysaccharide and an agent for introducing an electrophilic group, to an esterification reaction, wherein an active esterified polysaccharide is formed; bringing the active esterified polysaccharide into contact with a polyvalent carboxylic acid; and after the active esterified polysaccharide is brought into contact with the polyvalent carboxylic acid, precipitating and collecting the resulting active esterified polysaccharide.

Abstract: A metal electrolytic capacitor capable of quickly absorbing and immobilizing a belching vapor of a driving electrolyte and widely reducing leakage when an explosion-proof valve operates. An aluminum electrolytic capacitor body is configured by housing a capacitor element in a cylindrical aluminum case, a pair of leads extend from the capacitor body, an explosion-proof valve is formed on a top panel portion of the metal case, a cylindrical cap as a casing is attached from above to the capacitor body, a plurality of small openings are formed on a top panel portion (bottom portion) of the cap, and an absorbent or a mixture of an absorbent and a water molecular compound wrapped in a permeable fiber material, such as unwoven fabric and filter paper, is placed in a space between the cap and the top panel portion of the capacitor body.

Abstract: Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.

Abstract: Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.